title: Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome.
abstract: To provide a potentially therapeutic intervention and to collect clinical and laboratory data during an outbreak of hantavirus pulmonary syndrome (HPS), 140 patients from the United States with suspected HPS were enrolled for investigational intravenous ribavirin treatment. HPS was subsequently laboratory confirmed in 30 persons and not confirmed in 105 persons with adequate specimens. Patients with HPS were significantly more likely than were hantavirus-negative patients to report myalgias from onset of symptoms through hospitalization, nausea at outpatient presentation, and diarrhea and nausea at the time of hospitalization; they were significantly less likely to report respiratory symptoms early in the illness. The groups did not differ with regard to time from the onset of illness to the point at which they sought care; time from onset, hospitalization, or enrollment to death was significantly shorter for patients with HPS. At the time of hospitalization, patients with HPS more commonly had myelocytes, metamyelocytes, or promyelocytes on a peripheral blood smear, and significantly more of them had thrombocytopenia, hemoconcentration, and hypocapnia. Patterns of clinical symptoms, the pace of clinical evolution, and specific clinical laboratory parameters discriminated between these 2 groups.
authors.affiliation: Hantavirus Task Force, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. lec3@cdc.gov
authors.forename: L E
authors.initials: LE
authors.lastname: Chapman
authors.forename: B A
authors.initials: BA
authors.lastname: Ellis
authors.forename: F T
authors.initials: FT
authors.lastname: Koster
authors.forename: M
authors.initials: M
authors.lastname: Sotir
authors.forename: T G
authors.initials: TG
authors.lastname: Ksiazek
authors.forename: G J
authors.initials: GJ
authors.lastname: Mertz
authors.forename: P E
authors.initials: PE
authors.lastname: Rollin
authors.forename: K F
authors.initials: KF
authors.lastname: Baum
authors.forename: A T
authors.initials: AT
authors.lastname: Pavia
authors.forename: J C
authors.initials: JC
authors.lastname: Christenson
authors.forename: P J
authors.initials: PJ
authors.lastname: Rubin
authors.forename: H M
authors.initials: HM
authors.lastname: Jolson
authors.forename: R E
authors.initials: RE
authors.lastname: Behrman
authors.forename: A S
authors.initials: AS
authors.lastname: Khan
authors.forename: L J Wilson
authors.initials: LJ
authors.lastname: Bell
authors.forename: G L
authors.initials: GL
authors.lastname: Simpson
authors.forename: J
authors.initials: J
authors.lastname: Hawk
authors.forename: R C
authors.initials: RC
authors.lastname: Holman
authors.forename: C J
authors.initials: CJ
authors.lastname: Peters
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001784:Blood Gas Analysis; D004573:Electrolytes; D005260:Female; D006476:Orthohantavirus; D018778:Hantavirus Infections / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D007677:Kidney Function Tests; D008111:Liver Function Tests; D008171:Lung Diseases / Q000188:drug therapy* / Q000821:virology; D008297:Male; D010976:Platelet Count; D011517:Prothrombin Time; D012044:Regression Analysis; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D004573:Electrolytes; D012254:Ribavirin